# Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."

> **NCT07172724** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Federal University of Minas Gerais** · enrollment: 48 (estimated)

## Conditions studied

- Malaria Vivax

## Interventions

- **BIOLOGICAL:** Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07172724
- **Lead sponsor:** Federal University of Minas Gerais
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-03
- **Final completion:** 2027-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172724, "Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07172724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*